drugset / Trial / NCT00612209
A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open label, single arm, dose escalation study of ARQ 197 in patients with advanced solid tumors.
Timeline
- Start
- 2007-04
- Primary completion
- 2010-01
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tivantinib | Small molecule | 100 mg | Oral |
| Subject | Tivantinib | Small molecule | 200 mg | Oral |
| Subject | Tivantinib | Small molecule | 360 mg | Oral |
| Subject | Tivantinib | Small molecule | 400 mg | Oral |
Indications
No indication recorded.